Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$84.59 USD
+0.42 (0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $84.58 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Price, Consensus and EPS Surprise
GILD 84.59 +0.42(0.50%)
Will GILD be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GILD
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
Other News for GILD
Gilead just upgraded at Wells Fargo, here's why
Gilead price target raised by $8 at Barclays, here's why
Gilead Sciences (GILD) was upgraded to a Buy Rating at Wells Fargo
Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD)
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation